重症监护医学
药物发现
透视图(图形)
医学
药理学
风险分析(工程)
计算生物学
药品
药物开发
药效学
患者依从性
抗病毒药物
抗病毒治疗
病毒感染
持续时间(音乐)
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
钥匙(锁)
临床研究设计
2019年冠状病毒病(COVID-19)
生物信息学
合理设计
梅德林
临床试验
生化工程
管理科学
抗病毒治疗
2019-20冠状病毒爆发
化学
作者
Shuo Wang,Fareeda Ma,Craig W. Lindsley,Shujing Xu,Xinyong Liu,Peng Zhan
标识
DOI:10.1021/acs.jmedchem.5c01728
摘要
Long-acting antiviral agents present a promising strategy for overcoming the clinical challenges associated with viral infection management, such as suboptimal patient adherence, rapid viral rebound, and the emergence of resistance, while providing prolonged half-life, improved metabolic stability, and sustained drug exposure. This perspective systematically reviews recent advancements in the design and optimization of long-acting antivirals from a medicinal chemistry standpoint. We highlight key factors that contribute to sustained efficacy, including target binding kinetics, metabolic stability, depot formation, and physicochemical properties. Case studies illustrate how structural modifications can be employed to enhance systemic exposure and achieve prolonged pharmacodynamic effects. This perspective offers a comprehensive framework for the rational development of next-generation long-acting antivirals, with the aim of guiding innovations to improve treatment outcomes and patient compliance across a range of viral infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI